Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMMIT: Ublituximab in Early, Active, Autoantibody-Positive Immune-Mediated Necrotizing Myopathy
NCT07103746Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2026
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ublituximab in immune-mediated necrotizing myopathy (IMNM), sponsored by National Institute of Allergy and Infectious Diseases. Started Apr 2026; status: recruiting.
02
Drugs
ublituximab
03
Conditions
immune-mediated necrotizing myopathy (IMNM)
Beyond the preview
Go deeper on NCT07103746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07103746.